Claim 1: the drug composition includes one FXR playmaker, at least one PPAR-a playmaker, one ppar-d playmaker and / or one PPAR-a and double ppar-d playmaker, and one or more drug acceptable vehicles. 11. Claim 2: the pharmaceutical ingredient of claim 1, wherein at least one dying person of ppp-a is fiber. Claim 3: pharmaceutical ingredients in claim 2, in which fibers are selected from bezafibrato, cibrofiato, closerato, phenylcellulose, gemfibrosil, binifibrato, Clino fiber, clofbrico, nicofibrato, pirifibrato,1. Propylcellulose, arylcellulose, heptachlor, bacon, any of the acceptable salts, any of the acceptable esters and phenyl-2-methylpropionic acid derivatives. Among these derivatives, the phenyl unit has been replaced by a pyridine and a 4-hydroxypyridine； A substitute, or a substitute Claim 7: the pharmaceutical composition of claim 1, wherein the promoter of at least one ppp-d is {4 - [(4-methyl-2 - [(4 - (trifluoromethyl) phenyl] - 1,3-sulfur-5-il} methyl) sulfur] - 2-methylphenyl} acetic anhydride,{2-methyl-4- [5-methyl-2- (4-trifluoromethyl-phenyl) -2H- [1,2,3] triazol-4-ylmethylsilylphenyl] -phenoxy} -acetic acid, [4- [[[2- [3-Fluoro-4- (trifluoromethyl) phenyl] -4-methyl-5-thiazolyl] methyl] thio] -2-methylphenoxy] -acetic acid or a pharmaceutically acceptable salt of any of these. Claim 8: The pharmaceutical composition according to claim 1, wherein the at least one double agonist of PPAR-a and PPAR-d is 2- [2,6-dimethyl-4- [3- [4- ( methylthio) phenyl] -3-oxo-1 (E) -propenyl] phenoxyl] -2-methylpropanoic acid, (2S) -2-methoxy-3- [4- [2- (5-methyl-2-phenyl- 4-oxazolyl) ethoxy] -7-benzothiophenyl] propanoic acid,[1 - [1 - [1 - [1 - (1] YL] YL] YL] benzene [1 - [1 - [1 - [1 - [1 - [1 - [propane], or any of them, is an acceptable salt for medicine. 38. Claim 9: the composition of the drug in claim 1, which also includes one country. Claim 10: according to the pharmaceutical composition of claim 9, select a medicinal material between simvastatina, flava
